Trial Profile
Evaluation of the Long Term Safety of the Use of Dabigatran Etexilate in Patients With a Bileaflet Mechanical Heart Valve
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 15 Sep 2014
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary) ; Warfarin
- Indications Stroke; Thromboembolism; Thrombosis
- Focus Adverse reactions
- Acronyms RE-ALIGN-EX
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 17 Dec 2013 Results published in the Annals of Internal Medicine.
- 01 Jul 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 18 Feb 2013 New trial record